Shree Ganesh Remedies Ltd
Shree Ganesh Remedies is engaged in chemical
manufacturing, specialising in pharmaceutical
intermediates and speciality chemicals.[1]
- Market Cap ₹ 861 Cr.
- Current Price ₹ 671
- High / Low ₹ 950 / 558
- Stock P/E 30.6
- Book Value ₹ 104
- Dividend Yield 0.00 %
- ROCE 27.8 %
- ROE 26.9 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 35.1% CAGR over last 5 years
- Debtor days have improved from 88.5 to 58.9 days.
- Promoter holding has increased by 1.17% over last quarter.
- Company's median sales growth is 28.2% of last 10 years
Cons
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
13 | 18 | 16 | 16 | 20 | 27 | 35 | 58 | 49 | 71 | 91 | 126 | 123 | |
10 | 14 | 14 | 14 | 16 | 22 | 26 | 47 | 35 | 53 | 68 | 84 | 78 | |
Operating Profit | 2 | 5 | 2 | 2 | 4 | 5 | 9 | 11 | 14 | 18 | 23 | 42 | 45 |
OPM % | 19% | 25% | 13% | 12% | 21% | 19% | 25% | 19% | 28% | 25% | 26% | 33% | 37% |
1 | 1 | 0 | 0 | 0 | 2 | 1 | 4 | 2 | 4 | 1 | 3 | 3 | |
Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 3 | 4 | 6 | 8 |
Profit before tax | 2 | 5 | 2 | 2 | 4 | 6 | 9 | 13 | 13 | 18 | 20 | 38 | 38 |
Tax % | 33% | 32% | 33% | 34% | 33% | 28% | 28% | 24% | 25% | 26% | 25% | 26% | |
1 | 3 | 1 | 1 | 3 | 5 | 6 | 10 | 10 | 13 | 15 | 28 | 28 | |
EPS in Rs | 9.25 | 20.06 | 7.94 | 6.75 | 16.50 | 3.66 | 4.88 | 7.52 | 7.62 | 10.47 | 11.86 | 21.97 | 21.92 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 19% | 18% | 14% | 18% | 4% | 2% | 2% |
Compounded Sales Growth | |
---|---|
10 Years: | 21% |
5 Years: | 29% |
3 Years: | 37% |
TTM: | 10% |
Compounded Profit Growth | |
---|---|
10 Years: | 24% |
5 Years: | 35% |
3 Years: | 42% |
TTM: | 27% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 62% |
3 Years: | 26% |
1 Year: | 10% |
Return on Equity | |
---|---|
10 Years: | 22% |
5 Years: | 24% |
3 Years: | 24% |
Last Year: | 27% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 10 | 12 | 13 | 13 | 13 |
Reserves | 7 | 11 | 12 | 13 | 15 | 20 | 25 | 33 | 40 | 50 | 75 | 109 | 120 |
2 | 0 | 0 | 0 | 0 | 2 | 1 | 2 | 0 | 0 | 33 | 36 | 34 | |
2 | 2 | 2 | 2 | 5 | 5 | 7 | 8 | 10 | 15 | 18 | 12 | 11 | |
Total Liabilities | 12 | 15 | 15 | 16 | 21 | 36 | 41 | 52 | 61 | 77 | 138 | 171 | 178 |
4 | 4 | 4 | 4 | 4 | 6 | 14 | 16 | 19 | 27 | 58 | 81 | 97 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 15 | 17 | 3 |
Investments | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 7 | 3 | 0 | 0 | 5 | 7 |
8 | 10 | 11 | 11 | 17 | 25 | 23 | 29 | 37 | 47 | 64 | 69 | 72 | |
Total Assets | 12 | 15 | 15 | 16 | 21 | 36 | 41 | 52 | 61 | 77 | 138 | 171 | 178 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 5 | -1 | -2 | 2 | -1 | -5 | 4 | 3 | 13 | 17 | 30 | |
0 | -1 | 1 | 1 | 0 | -3 | -0 | -3 | -1 | -12 | -51 | -33 | |
-1 | -0 | -0 | -0 | -0 | 8 | -0 | -0 | -1 | -1 | 39 | 10 | |
Net Cash Flow | 0 | 3 | -1 | -0 | 2 | 4 | -5 | 1 | 2 | 0 | 5 | 7 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 100 | 45 | 93 | 133 | 136 | 78 | 101 | 104 | 99 | 94 | 112 | 59 |
Inventory Days | 186 | 126 | 132 | 130 | 103 | 102 | 125 | 56 | 206 | 132 | 138 | 156 |
Days Payable | 47 | 23 | 43 | 32 | 90 | 43 | 75 | 39 | 101 | 92 | 118 | 51 |
Cash Conversion Cycle | 239 | 149 | 183 | 232 | 149 | 137 | 151 | 120 | 205 | 134 | 133 | 164 |
Working Capital Days | 187 | 96 | 160 | 202 | 172 | 156 | 149 | 115 | 159 | 133 | 132 | 110 |
ROCE % | 25% | 44% | 16% | 12% | 26% | 27% | 27% | 33% | 28% | 33% | 22% | 28% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Earnings Call Transcript 12 Nov
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
10 Nov - Audio recording of earnings call on November 8, 2024.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
4 Nov - Q2 & H1FY25 Earnings Conference Call Invitation
- Announcement under Regulation 30 (LODR)-Newspaper Publication 31 Oct
-
Announcement under Regulation 30 (LODR)-Investor Presentation
30 Oct - Investor presentation for Q2 & H1FY25 results.
Evolution of Business[1]
The company is changing its focus from Intermediates for Off-patent and generic drugs towards patented molecules requiring strong technical know how. The revenue contribution from Intermediates has also shifted from 90% to <60%.